Acquired Blepharoptosis

• CLINICAL_TRIALS research · 2025-03-20
  Clinical Trial Update: LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. [Phase 3]

  Phase 3 study evaluating the efficacy and safety of STN1013800 (oxymetazoline HCl 0.1% eye drops) for the treatment of acquired blepharoptos…

• CLINICAL_TRIALS trial_result · 2024-11-13
  Clinical Trial Update: LEV102 Topical Gel in Acquired Blepharoptosis [Phase 1, Phase 2]

  LEV102 topical gel from Levation Pharma completed Phase 1/2 trials for acquired blepharoptosis, with results posted.

• CLINICAL_TRIALS trial_result · 2020-10-20
  Clinical Trial Update: Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis [Phase 3]

  A Phase 3 clinical trial completed evaluating RVL-1201 for Acquired Blepharoptosis with results posted in 2020.

• FDA approval · 2020-08-14
  FDA Approved: UPNEEQ — Supplemental Application (RVL Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for UPNEEQ (oxymetazoline hydrochloride ophthalmic solution) from RVL Pharmaceuticals, Inc., ref…

• FDA approval · 2020-07-08
  FDA Approved: UPNEEQ — Original Application (RVL Pharmaceuticals, Inc.)

  FDA approved Upneeq (oxymetazoline hydrochloride ophthalmic solution) from RVL Pharmaceuticals as the first approved treatment for acquired …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.